Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The radiolabelled growth factor [(123/125)I] I-hEGF is evaluated in vitro and in vivo to monitor the acute effects on the EGFR of R115777, a farnesyl transferase inhibitor (FTI). Upregulation of the EGFR after incubation with R115777 correlated linearly with FTI induced acute growth inhibition. Receptor mediated [125I] I-hEGF internalization decreased following R115777 treatment. Preliminary data suggest that the net in vivo effect is a decrease of [123I] I-hEGF uptake in the tumour. These findings suggest the possible use of radioiodinated hEGF as a radiodiagnosticum to investigate EGFR status changes as a predictor for eventual FTI chemotherapy outcome in vivo.

Original publication




Journal article


Nucl Med Biol

Publication Date





679 - 689


Alkyl and Aryl Transferases, Animals, Cell Line, Enzyme Inhibitors, Epidermal Growth Factor, ErbB Receptors, Farnesyltranstransferase, Humans, Iodine Radioisotopes, Magnetic Resonance Imaging, Male, Mice, Mice, Nude, Neoplasm Transplantation, Quinolones, Radiopharmaceuticals, Regression Analysis, Tissue Distribution